Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.

NCT05853367 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT05853367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05853367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 6, 2023
Completion date
June 24, 2028
Enrollment
95 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, metastatic solid tumors